domains/grand-strategy/ai-weapons-stigmatization-campaign-has-normative-infrastructure-without-triggering-event-creating-icbl-phase-equivalent-waiting-for-activation.md

@@ -24,6 +24,12 @@ The Campaign to Stop Killer Robots (CS-KR) was founded in April 2013 with ~270 m
 
 Loitering munitions specifically show declining strategic exclusivity (non-state actors already have Shahed-136 technology) and increasing civilian casualty documentation (Ukraine, Gaza), creating conditions for stigmatization — though not yet generating ICBL-scale response. The barrier is the triggering event, not permanent structural impossibility. Autonomous naval mines provide even clearer stigmatization path because civilian shipping harm is direct analog to civilian populations in mined territory under Ottawa Treaty.
 
+### Additional Evidence (extend)
+*Source: [[2026-04-01-leo-fda-pharmaceutical-triggering-event-governance-cycles]] | Added: 2026-04-01*
+
+The pharmaceutical case adds a critical boundary condition: the timing of disaster relative to advocacy infrastructure matters. Thalidomide hit when Kefauver's infrastructure was already in place (three years of legislative effort), producing rapid governance. Sulfanilamide hit without comparable advocacy infrastructure, producing slower reform. This suggests AI weapons stigmatization infrastructure is valuable even before a triggering event, because pre-existing infrastructure accelerates the disaster-to-governance translation when the event occurs.
+
+
 
 Relevant Notes:
 - [[the-legislative-ceiling-on-military-ai-governance-is-conditional-not-absolute-cwc-proves-binding-governance-without-carveouts-is-achievable-but-requires-three-currently-absent-conditions]]

domains/grand-strategy/pharmaceutical-governance-advances-required-triggering-events-not-incremental-advocacy-because-kefauver-three-year-blockage-preceded-thalidomide-breakthrough.md

@@ -0,0 +1,26 @@
+---
+type: claim
+domain: grand-strategy
+description: Senator Kefauver's 1959-1962 drug reform efforts were completely blocked by industry lobbying despite technical expertise and political will, until the thalidomide disaster broke the logjam in months
+confidence: likely
+source: FDA regulatory history, congressional record, documented in Carpenter 'Reputation and Power'
+created: 2026-04-01
+attribution:
+  extractor:
+    - handle: "leo"
+  sourcer:
+    - handle: "leo"
+      context: "FDA regulatory history, congressional record, documented in Carpenter 'Reputation and Power'"
+---
+
+# Pharmaceutical governance advances required triggering events not incremental advocacy because Kefauver's three-year blockage preceded thalidomide breakthrough
+
+The pharmaceutical governance record from 1906-1962 establishes that triggering events are necessary, not merely sufficient, for technology-governance coupling. Three major governance advances occurred, and all three required disasters: (1) The 1938 Food, Drug, and Cosmetic Act passed within one year of the sulfanilamide disaster (107 deaths, primarily children) after the FDA had existed since 1906 without pre-market safety authority. (2) The 1962 Kefauver-Harris Amendments required proof of efficacy and established modern clinical trials, but only after thalidomide caused 8,000-12,000 birth defects in Europe. Critically, Senator Kefauver had spent THREE YEARS (1959-1962) attempting to pass drug reform through systematic legislative argument. Industry lobbying blocked it completely. The thalidomide disaster broke the blockage in months, producing what years of advocacy could not. (3) The 1992 PDUFA responded to HIV/AIDS activist pressure (25,000-35,000 deaths/year) demanding faster approvals. The pattern is consistent: incremental advocacy without disaster produced zero binding governance. Internal FDA scientists raised safety concerns for years before 1937 without producing the 1938 Act. Kefauver's three-year effort with technical expertise and political will produced nothing until thalidomide. This quantifies what 'advocacy without triggering event' produces: complete blockage by industry interests. The pharmaceutical case is the cleanest single-domain confirmation that triggering-event architecture is the dominant mechanism for technology-governance coupling.
+
+---
+
+Relevant Notes:
+- voluntary-safety-commitments-collapse-under-competitive-pressure-because-coordination-mechanisms-like-futarchy-can-bind-where-unilateral-pledges-cannot
+
+Topics:
+- [[_map]]

domains/grand-strategy/triggering-event-architecture-requires-three-components-infrastructure-disaster-champion-confirmed-across-pharmaceutical-and-arms-control-domains.md

@@ -0,0 +1,26 @@
+---
+type: claim
+domain: grand-strategy
+description: Cross-domain evidence from pharmaceutical governance (1906-1962) and arms control (ICBL) independently confirms the same three-component mechanism
+confidence: likely
+source: FDA regulatory history (sulfanilamide 1937, thalidomide 1961), ICBL case from Session 2026-03-31
+created: 2026-04-01
+attribution:
+  extractor:
+    - handle: "leo"
+  sourcer:
+    - handle: "leo"
+      context: "FDA regulatory history (sulfanilamide 1937, thalidomide 1961), ICBL case from Session 2026-03-31"
+---
+
+# Triggering-event architecture requires three components infrastructure disaster champion confirmed across pharmaceutical and arms control domains
+
+The three-component triggering-event architecture is now confirmed across two independent domains. Component 1 (infrastructure): Pre-existing institutional capacity and advocacy networks that can rapidly translate disaster into governance. In pharmaceuticals: FDA's 1906 mandate, internal safety advocates, Kefauver's ready legislation. In arms control: ICBL's decade of advocacy infrastructure before Princess Diana. Component 2 (triggering event): Visible, attributable, emotionally resonant harm. In pharmaceuticals: sulfanilamide's 107 child victims (1937), thalidomide's photographed birth defects (1961). In arms control: landmine victim photographs, Princess Diana's advocacy. Component 3 (champion moment): A specific actor who converts disaster into legislative action. In pharmaceuticals: Senator Kefauver (who had the ready bill), Frances Kelsey (who had blocked thalidomide). In arms control: Lloyd Axworthy. The timing relationship matters: disasters that hit when advocacy infrastructure is already in place (thalidomide + Kefauver's three-year effort) produce faster governance than disasters without infrastructure (sulfanilamide). The emotional resonance is not incidental—it is the mechanism by which political will is generated faster than industry lobbying can neutralize. This cross-domain confirmation elevates confidence from experimental (single domain) to likely (two independent domains with the same mechanism).
+
+---
+
+Relevant Notes:
+- [[ai-weapons-stigmatization-campaign-has-normative-infrastructure-without-triggering-event-creating-icbl-phase-equivalent-waiting-for-activation]]
+
+Topics:
+- [[_map]]

inbox/queue/2026-04-01-leo-fda-pharmaceutical-triggering-event-governance-cycles.md

@@ -7,9 +7,14 @@ date: 2026-04-01
 domain: grand-strategy
 secondary_domains: [mechanisms]
 format: synthesis
-status: unprocessed
+status: processed
 priority: high
 tags: [fda, pharmaceutical, triggering-event, sulfanilamide, thalidomide, regulatory-reform, kefauver-harris, technology-coordination-gap, enabling-conditions, belief-1, disconfirmation]
+processed_by: leo
+processed_date: 2026-04-01
+claims_extracted: ["pharmaceutical-governance-advances-required-triggering-events-not-incremental-advocacy-because-kefauver-three-year-blockage-preceded-thalidomide-breakthrough.md", "triggering-event-architecture-requires-three-components-infrastructure-disaster-champion-confirmed-across-pharmaceutical-and-arms-control-domains.md"]
+enrichments_applied: ["ai-weapons-stigmatization-campaign-has-normative-infrastructure-without-triggering-event-creating-icbl-phase-equivalent-waiting-for-activation.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -100,3 +105,15 @@ PRIMARY CONNECTION: [[the triggering-event architecture claim from research-2026
 WHY ARCHIVED: Provides the strongest empirical evidence that triggering events are necessary (not just sufficient) for technology-governance coupling; also confirms three-component mechanism across an independent domain
 
 EXTRACTION HINT: Extract as evidence for the "triggering-event architecture as cross-domain mechanism" claim (Candidate 2 in research-2026-04-01.md); pair with the arms control triggering-event evidence for a high-confidence cross-domain claim
+
+
+## Key Facts
+- 1906 Pure Food and Drug Act prohibited adulterated or misbranded food and drugs but required no pre-market safety approval
+- 1937 Massengill Sulfanilamide Elixir Disaster killed 107 people, primarily children, when the company dissolved sulfa drug in toxic diethylene glycol without toxicity testing
+- 1938 Food, Drug, and Cosmetic Act passed within one year of sulfanilamide disaster, requiring pre-market safety testing
+- Thalidomide caused approximately 8,000-12,000 birth defects in Europe, Canada, and Australia between 1959-1962
+- Frances Kelsey at FDA blocked US thalidomide approval 1960-1961 despite industry pressure, largely sparing the US
+- Senator Estes Kefauver attempted drug reform legislation from 1959-1962, blocked by industry lobbying for three years
+- 1962 Kefauver-Harris Drug Amendments required proof of efficacy (not just safety) and established modern clinical trial framework
+- 1992 Prescription Drug User Fee Act responded to HIV/AIDS epidemic with 25,000-35,000 deaths/year in US by early 1990s
+- Average drug approval time was 30 months before PDUFA, reduced to 6 months for priority review after